Biotechnology
(TECH) Techne Corporation - two operating divisions, which are Hematology and Biotechnology
Techne Corp. (TECH) has seen upward estimate revisions from Wall Street. For the year ending June 2009, Analyst forecasts of $2.93 per share were increased from $2.89 over the past 60 days. Company Description Techne Corporation develops and manufactures biotechnology products...
23Dec2008 | Shawn | 0 comments | Continued(EBS) Emergent BioSolutions, Inc - Revenue came in at $56.6 million, a 30% increase from last year
Emergent BioSolutions, Inc. (EBS) is aggressively growing its earnings, recently reporting impressive third-quarter results that marked big gains from the previous year. Analysts are very bullish on the company, with the next-year estimate projecting 100% earnings growth. Company...
8Dec2008 | Shawn | 0 comments | Continued(VPHM) ViroPharma Inc - Sales are expected to grow 159.26%
ViroPharma Inc. (VPHM) is seeing record sales of its big drug Vancocin which is adding to its already sizable cash hoard. Sales are expected to grow 159.26%. VPHM is an attractive value stock. ViroPharma is trading with a price-to-book of 1.44. Company Description ViroPharma...
4Dec2008 | Shawn | 0 comments | Continued(QCOR) Questor Pharmaceuticals - current-year estimate is up 12 cents to 46 cents per share in the last 30 days
Questor Pharmaceuticals, Inc. (QCOR) is successfully growing its cash flow from operations, which the company is using to stimulate its share price with ongoing buyback efforts. Analyst are bullish on the company, with an 11% earnings growth projection in the next-year period. Company...
26Nov2008 | Shawn | 0 comments | Continued(TECH) Techne Corp - company’s return on equity (ROE) of 23% is high above the industry average
Techne Corp. (TECH), a Zacks #1 Rank (“strong buy”), recently declared a quarterly dividend of 25 cents per share thanks to the company’s solid performance. Techne is yielding 1.5%, which is well ahead of the industry average as most of the company’s industry peers pay...
20Nov2008 | Shawn | 0 comments | Continued(AMGN) Consensus Estimates for the Fourth Quarter and the Full Year Rise
Amgen, Inc. (AMGN) recently raised 2008 EPS guidance after strong sales in its third-quarter. The company has surprised on estimates 4 consecutive quarters by an average of 10.68%. AMGN is trading at 11.9x forward earnings. Company Description Amgen manufactures human therapeutics...
29Oct2008 | Shawn | 0 comments | Continued